AbbVie (NYSE:ABBV) Stock Rating Lowered by Wall Street Zen

AbbVie (NYSE:ABBV) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Other analysts have also issued reports about the stock. Guggenheim raised their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Wells Fargo & Company lifted their price target on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Stock Performance

ABBV opened at $229.26 on Friday. The stock has a market capitalization of $405.19 billion, a PE ratio of 173.68, a price-to-earnings-growth ratio of 0.96 and a beta of 0.36. The stock’s 50 day moving average price is $226.69 and its 200-day moving average price is $214.14. AbbVie has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business posted $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie will post 12.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie during the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter valued at $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter valued at $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the 2nd quarter worth about $28,000. Finally, Texas Capital Bancshares Inc TX purchased a new position in AbbVie in the 3rd quarter worth about $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.